Tislelizumab and anlotinib for thymus cancer after first treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of two drugs (tislelizumab and anlotinib) as a second treatment option for people with thymoma or thymic carcinoma whose cancer has worsened after first-line therapy. It aims to see if this combination can control the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with thymoma or thymic carcinoma.
- Your cancer got worse during or after your first treatment (chemotherapy with or without immunotherapy).
- You have not taken anlotinib or similar anti-angiogenesis drugs before.
- You do not have an active autoimmune disease.
- Your heart, liver, kidney, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug called adebrelimab to chemotherapy and radiation before surgery can help shrink thymic cancer and improve outcomes. It is for people with locally advanced thymic carcinoma that can potentially be removed with surgery.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests whether adding two medications—tislelizumab (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted drug that blocks blood supply to tumors)—after standard chemoradiation can help keep limited-stage small cell lung cancer from coming back. It may offer a new option to improve outcomes for patients who have already responded to initial treatment.
This study tests a new drug called sacituzumab tirumotecan for people with advanced thymus tumors that have already been treated once. The drug is given as an infusion and may help control the tumor.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Hear when a new Thymic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.